← All trials
NCT03280056
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2017
- Primary completion
- Apr 30, 2019
- Completion date
- Jul 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Brainstorm Cell TherapeuticsLead sponsor
- Cedars-Sinai Medical CenterOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- University of California, IrvineOverall official - principal investigator
- University of MassachusettsOverall official - principal investigator
- California Pacific Medical Center Research InstituteOverall official - principal investigator
- California Institute for Regenerative Medicine (CIRM)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.